论文部分内容阅读
目的 :比较IM -EP方案[即IFNα1b(赛若金 )、MA(megestrolacetate ,甲地孕酮 )、VP16 与PDD联合的生物化疗方案]与EP方案 (即VP16 加PDD的单纯化疗方案 )对初治Ⅲb～Ⅳ期非小细胞肺癌 (NSCLC)病人的疗效、毒性及生活质量的改善情况。方法 :A组 (33例 )接受IM -EP方案治疗 ;B组 (35例 )接受EP方案治疗。两组均以4wk为1周期 ,重复3个周期。客观疗效与毒性反应按WHO标准进行评价 ,生活质量根据临床受益疗效来评价。结果 :A、B两组客观疗效 (CR +PR)分别为27 3 %及22 9 % ,P>0 05 ;中位生存期A组32周 ,B组27周 (P<0 01) ;白细胞减少及恶心呕吐反应B组均较A组明显 (P<0 01) ;短暂性寒战、发热症状多见于A组 (P<0 01) ;两组均未发现其他严重的毒性反应。临床受益疗效A组高于B组 (P<0 05)。结论 :赛若金、甲地孕酮配合EP方案与单纯EP方案治疗晚期NSCLC的客观疗效无明显差异性 ,但前者毒副反应小 ,中位生存期长 ,病人生活质量改善明显
PURPOSE: To compare the effects of IM -EP regimen (ie, IFNα1b, megestrolacetate (MA), biochemotherapy with VP16 and PDD) and EP (the chemotherapy regimen with VP16 plus PDD) Efficacy, toxicity and quality of life of patients with stage Ⅲb-Ⅳ non-small cell lung cancer (NSCLC). Methods: Group A (33 cases) received IM -EP regimen; Group B (35 cases) received EP regimen. Both groups were 4wk 1 cycle, repeat 3 cycles. Objective efficacy and toxicity response to WHO standards for evaluation, quality of life based on clinical benefit evaluation. Results: The objective response (CR + PR) in group A and group B were 27.3% and 22.9%, respectively, P> 0.05. The median survival time was 32 weeks in group A and 27 weeks in group B (P <0.01) The reduction and nausea and vomiting responses in group B were significantly higher than those in group A (P <0.01). The transient chills and fever were more common in group A (P <0.01). No other serious toxicity was found in both groups. The clinical benefit of A group was higher than that of B group (P <0.05). Conclusion: There is no significant difference in the objective curative effect of racemargin, megestrol combined with EP regimen and simple EP regimen in the treatment of advanced NSCLC. However, the former has small toxic side effects, long median survival time and significant improvement in patients’ quality of life